4.7 Article

Bone Marrow Transplantation Confers Modest Benefits in Mouse Models of Huntington's Disease

期刊

JOURNAL OF NEUROSCIENCE
卷 32, 期 1, 页码 133-142

出版社

SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.4846-11.2012

关键词

-

资金

  1. J. David Gladstone Institutes
  2. Taube-Koret Center for Huntington's Disease Research
  3. Natural Sciences and Engineering Research Council, Canada
  4. National Institutes of Health [P30NS065780]
  5. Medical Research Council [MR/J003832/1] Funding Source: researchfish
  6. MRC [MR/J003832/1] Funding Source: UKRI

向作者/读者索取更多资源

Huntington's disease (HD) is caused by an expanded polyglutamine tract in the protein huntingtin (htt). Although HD has historically been viewed as a brain-specific disease, htt is expressed ubiquitously, and recent studies indicate that mutant htt might cause changes to the immune system that could contribute to pathogenesis. Monocytes from HD patients and mouse models are hyperactive in response to stimulation, and increased levels of inflammatory cytokines and chemokines are found in pre-manifest patients that correlate with pathogenesis. In this study, wild-type (WT) bone marrow cells were transplanted into two lethally irradiated transgenic mouse models of HD that ubiquitously express full-length htt (YAC128 and BACHD mice). Bone marrow transplantation partially attenuated hypokinetic and motor deficits in HD mice. Increased levels of synapses in the cortex were found in HD mice that received bone marrow transplants. Importantly, serum levels of interleukin-6, interleukin-10, CXC chemokine ligand 1, and interferon-gamma were significantly higher in HD than WT mice but were normalized in mice that received a bone marrow transplant. These results suggest that immune cell dysfunction might be an important modifier of pathogenesis in HD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Clinical Neurology

An MDS Evidence-Based Review on Treatments for Huntington's Disease

Joaquim J. Ferreira, Filipe B. Rodrigues, Goncalo S. Duarte, Tiago A. Mestre, Anne-Catherine Bachoud-Levi, Anna Rita Bentivoglio, Jean-Marc Burgunder, Francisco Cardoso, Daniel O. Claassen, G. Bernard Landwehrmeyer, Jaime Kulisevsky, Melissa J. Nirenberg, Anne Rosser, Jan Roth, Klaus Seppi, Jaroslaw Slawek, Erin Furr-Stimming, Sarah J. Tabrizi, Francis O. Walker, Wim Vandenberghe, Joao Costa, Cristina Sampaio

Summary: The management of Huntington's disease (HD) is challenging and mainly consists of off-label treatments. A task force was commissioned to review available therapies for HD gene expansion carriers. Limited data supports the use of VMAT2 inhibitors for specific motor symptoms.

MOVEMENT DISORDERS (2022)

Article Psychology, Clinical

Opportunity cost determines free-operant action initiation latency and predicts apathy

Akshay Nair, Ritwik K. Niyogi, Fei Shang, Sarah J. Tabrizi, Geraint Rees, Robb B. Rutledge

Summary: This study provides new insights into understanding and explaining apathy, a disabling neuropsychiatric symptom, by investigating the relationship between the opportunity cost of time (OCT), self-initiation, and apathy. The findings suggest that OCT is an important variable for determining free-operant action initiation and understanding apathy.

PSYCHOLOGICAL MEDICINE (2023)

Article Neuroimaging

Timing of selective basal ganglia white matter loss in premanifest Huntington's disease

Paul Zeun, Peter McColgan, Thijs Dhollander, Sarah Gregory, Eileanoir B. Johnson, Marina Papoutsi, Akshay Nair, Rachael Scahill, Geraint Rees, Sarah J. Tabrizi

Summary: The study found that cortico-basal ganglia white matter loss begins in premanifest Huntington's disease (preHD) approximately 11 years before symptom onset. The most vulnerable white matter tracts are those connecting the striatum and thalamus. Additionally, there is a significant correlation between fiber density and cross section in these tracts and the Unified Huntington's disease rating scale (UHDRS) total motor score (TMS).

NEUROIMAGE-CLINICAL (2022)

Letter Clinical Neurology

CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy-like Phenotype

Ramita Dewan, Zane Jaunmuktane, Monica Emili Garcia-Segura, Catherine Strand, Edward Wild, Joaquin Villar, Clifton L. Dalgard, Sarah J. Tabrizi, Bryan J. Traynor, Christos Proukakis

MOVEMENT DISORDERS (2022)

Article Multidisciplinary Sciences

Expert-augmented automated machine learning optimizes hemodynamic predictors of spinal cord injury outcome

Austin Chou, Abel Torres-Espin, Nikos Kyritsis, J. Russell Huie, Sarah Khatry, Jeremy Funk, Jennifer Hay, Andrew Lofgreen, Rajiv Shah, Chandler McCann, Lisa U. Pascual, Edilberto Amorim, Philip R. Weinstein, Geoffrey T. Manley, Sanjay S. Dhall, Jonathan Z. Pan, Jacqueline C. Bresnahan, Michael S. Beattie, William D. Whetstone, Adam R. Ferguson

Summary: Artificial intelligence and machine learning have the potential to transform biomedicine by optimizing predictive models and enhancing understanding of disease biology. Automated machine learning, in particular, can democratize AI by reducing the need for human input and expertise. However, successful application of AI and machine learning in biomedicine requires reproducible clinical and biological inferences, which is challenging for rare disorders with small patient cohorts. A model-agnostic framework that incorporates explainable and reproducible AI strategies is proposed to enhance AutoML and facilitate clinical interpretation and integration of expert knowledge.

PLOS ONE (2022)

Article Computer Science, Information Systems

Mixture Model Framework for Traumatic Brain Injury Prognosis Using Heterogeneous Clinical and Outcome Data

Alan D. Kaplan, Qi Cheng, K. Aditya Mohan, Lindsay D. Nelson, Sonia Jain, Harvey Levin, Abel Torres-Espin, Austin Chou, J. Russell Huie, Adam R. Ferguson, Michael McCrea, Joseph Giacino, Shivshankar Sundaram, Amy J. Markowitz, Geoffrey T. Manley

Summary: In this study, a method for modeling heterogeneous data types relevant to TBI was developed to depict the nuanced differences in TBI patients' recovery. The model was trained on various data types and used to infer outcomes based on input data. Additionally, the performance of a likelihood scoring technique for evaluating the risk of prognosis extrapolation was quantified.

IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS (2022)

Article Neurosciences

PolyQ length-dependent metabolic alterations and DNA damage drive human astrocyte dysfunction in Huntington's disease

Jenny Lange, Olivia Gillham, Michael Flower, Heather Ging, Simon Eaton, Sneha Kapadia, Andreas Neueder, Michael R. Duchen, Patrizia Ferretti, Sarah J. Tabrizi

Summary: Huntington's Disease is a neurodegenerative disease caused by a genetic mutation. Astrocyte dysfunction, specifically changes in gene expression and metabolic activity, plays a role in the pathogenesis of the disease. Additionally, all Huntington's Disease astrocytes exhibit increased DNA damage and a DNA damage response, suggesting a potential mechanism for their dysfunction.

PROGRESS IN NEUROBIOLOGY (2023)

Editorial Material Neurosciences

Advance Care Planning in Huntington's Disease

Mena Farag, Desiree M. Salanio, Cara Hearst, Daniela Rae, Sarah J. Tabrizi

Summary: Advance care planning (ACP) is a beneficial tool that allows adult patients to express and formalize their beliefs, preferences, and wishes regarding future medical care. For Huntington's disease (HD) patients, early consideration of ACP is crucial due to challenges in determining decision-making capacity in the later stages of the disease. ACP empowers patients and provides reassurance to clinicians and surrogate decision makers by ensuring that medical management aligns with the patient's expressed wishes. Regular follow-up is necessary to maintain consistency in decisions and wishes. We outline the framework of our dedicated ACP clinic within the HD service, emphasizing the importance of patient-centered and personalized care plans that reflect the patient's goals, preferences, and values.

JOURNAL OF HUNTINGTONS DISEASE (2023)

Article Clinical Neurology

A PET-CT study on neuroinflammation in Huntington's disease patients participating in a randomized trial with laquinimod

Andreas-Antonios Roussakis, Marta Gennaro, Mark Forrest Gordon, Ralf Reilmann, Beth Borowsky, Gail Rynkowski, Nicholas P. Lao-Kaim, Zoe Papoutsou, Juha-Matti Savola, Michael R. Hayden, David R. Owen, Nicola Kalk, Anne Lingford-Hughes, Roger N. Gunn, Graham Searle, Sarah J. Tabrizi, Paola Piccini

Summary: This longitudinal study demonstrates that the treatment of laquinimod in Huntington's disease does not affect regional microglia activation. Microglia activation is believed to be related to inflammation in the central nervous system and the progression of Huntington's disease. However, laquinimod is capable of regulating microglia. The study also shows that C-11-PBR28 PET-CT imaging can be used to assess regional gliosis and the effects of laquinimod treatment.

BRAIN COMMUNICATIONS (2023)

Review Biochemistry & Molecular Biology

Genetic modifiers of repeat expansion disorders

Sangeerthana Rajagopal, Jasmine Donaldson, Michael Flower, Davina J. Hensman Moss, Sarah J. Tabrizi

Summary: Repeat expansion disorders (REDs) are monogenic diseases caused by repetitive DNA sequences expanding beyond a pathogenic threshold. The length of the repeat sequence is a major determinant of age at onset and disease progression. Phenotypic variability in REDs is influenced by factors such as the gene involved, the location of the repeat sequence, and the presence of interruptions. DNA repair pathways have been identified as potential modifiers of RED phenotypes, offering potential targets for disease-modifying therapies.

EMERGING TOPICS IN LIFE SCIENCES (2023)

Article Clinical Neurology

Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease

Chin-Fu Liu, Laurent Younes, Xiao J. Tong, Jared T. Hinkle, Maggie Wang, Sanika Phatak, Xin Xu, Xuan Bu, Vivian Looi, Jee Bang, Sarah J. Tabrizi, Rachael Scahill, Jane S. Paulsen, Nellie Georgiou-Karistianis, Andreia Faria, Michael Miller, J. Tilak Ratnanather, Christopher A. Ross

Summary: Huntington's disease is caused by a CAG repeat expansion in the Huntingtin gene, resulting in increased polyglutamine in the Huntingtin protein. This study analyzed three longitudinal datasets and found significant selective atrophy in multiple regions, supporting the hypothesis of circuit-based spread of pathology in Huntington's disease.

BRAIN COMMUNICATIONS (2023)

Meeting Abstract Clinical Neurology

INFLUENCING HUNTINGTON'S DISEASE MONITORING AND THERAPEUTIC DEVELOPMENT WITH REMOTE QUANTIFICATION OF BLOOD NEUROFILAMENT LIGHT PROTEIN

Lauren M. Byrne, Jordan L. Schultz, Sophie Field, Kate Fayer, Yara Hassan, Filipe B. Rodrigues, Ellen van der Plas, Douglas Langbehn, Sarah J. Tabrizi, Peggy C. Nopoulos, Edward J. Wild

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Meeting Abstract Clinical Neurology

IN VIVO INVESTIGATION OF PERIVASCULAR SPACES IN HUNTINGTON'S DISEASE USING T2-W 3T MRI

Annabelle Coleman, Mackenzie T. Langan, Gaurav Verma, Harry Knights, Rachelle Dar Santos, Allison Coleman, Aaron Sturrock, Blair R. Leavitt, Sarah J. Tabrizi, Rachael I. Scahill, Nicola Z. Hobbs

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Meeting Abstract Clinical Neurology

THE ROLE OF FAN1 NUCLEASE ACTIVITY AND MLH1 BINDING IN STABILISATION OF THE CAG REPEAT IN HD-IPSC DERIVED MODELS

Jasmine Donaldson, Joseph Hamilton, Jessica Olive, Robert Goold, Sarah J. Tabrizi

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Meeting Abstract Clinical Neurology

A CRISPRI PLATFORM TO ASSESS THE ROLE OF HD RISK MODIFIERS IN CAG REPEAT EXPANSION IN IPSC DERIVED STRIATAL NEURONS

Ross Ferguson, Michael Flower, Sarah J. Tabrizi

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

暂无数据